Why the study?
Transcatheter aortic valve replacement has transformed severe aortic stenosis treatment, but early experience with transcatheter mitral valve replacement requires evaluation.
Key points are not available for this paper at this time.
Design
Review
TAVR benefit in inoperable AS supports transcatheter strategies; leaves open TMVR translation to mitral populations.
Over the past decade, transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of patients with severe aortic stenosis (AS). TAVR gained a foothold as a viable aortic valve replacement (AVR) strategy in patients deemed inoperable, and early clinical trials in this setting confirmed a clear and dramatic survival advantage of TAVR over palliative medical therapy (1).
No takes yet. Share an insight, caveat, or question.
Huded et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: